- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00417248
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Outline: This is a multi-center study.
Chemotherapy/radiation therapy (2 cycles)
- Cisplatin 50 mg/m2 IV days 1 and 8 of 28 day cycle
- Etoposide 50 mg/m2 IV days 1-5 of 28 day cycle
- Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy) with the following:
Maintenance therapy of Sorafenib 400 mg PO BID of 28 day cycle, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 1 year.
Patients with progressive disease will discontinue treatment.
ECOG performance status 0 or 1
Hematopoietic:
- Absolute neutrophil count (ANC) ≥ 1500 mm3
- Platelet count ≥ 100,000 mm3
- Hemoglobin ≥ 9 g/dL
- PT or INR < 1.5 x ULN unless on anti-coagulant therapy
- PTT < 1.5 x ULN unless on anti-coagulant therapy
Hepatic:
- Bilirubin ≤ 1.5 x ULN
- ALT ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
- AST ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
Renal:
- Creatinine < 1.5 X upper limit of normal (ULN)
Cardiovascular:
- No significant history of cardiac disease: Congestive heart failure > class II NYHA.
- Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within 90 days prior to registration for initial therapy) or myocardial infarction within 6 months prior to registration for initial therapy.
Respiratory:
- FEV1 ≥ 1 liter by spirometry within 60 days prior to registration for initial therapy.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Illinois
-
Galesburg, Illinois, États-Unis, 61401
- Medical & Surgical Specialists, LLC
-
-
Indiana
-
Fort Wayne, Indiana, États-Unis, 46815
- Fort Wayne Oncology & Hematology, Inc
-
Goshen, Indiana, États-Unis, 46527
- Center for Cancer Care at Goshen Health System
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University Cancer Center
-
Lafayette, Indiana, États-Unis, 47905
- Horizon Oncology Center
-
Muncie, Indiana, États-Unis, 47303
- Medical Consultants, P.C.
-
South Bend, Indiana, États-Unis, 46601
- Northern Indiana Cancer Research Consortium
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45247
- Oncology Partners Network
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histological or cytological proof of non-small cell lung cancer (NSCLC).
- Measurable or non-measurable disease per RECIST.
- Unresectable Stage IIIA or IIIB disease as evaluated by imaging.
- Must be age ≥ 18 years at the time of consent.
- Written informed consent and HIPAA authorization for release of personal health information.
- Females of childbearing potential and males must be willing to use an effective method of contraception.
- Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for initial therapy.
Exclusion Criteria:
- No prior chemotherapy or radiotherapy for lung cancer.
- No positive supraclavicular or scalene lymph nodes extending up into the cervical region.
- No superior sulcus (pancoast tumors).
- No malignant pleural effusions. The only exception is a patient with a pleural effusion visible only on CT scan (and not visible on CXR) OR deemed too small to tap.
- No clinically significant or malignant pericardial effusions.
- No CNS metastases.
- No unintended weight loss (> 5% body weight) in the preceding 90 days prior to registration for initial therapy.
- No treatment with any investigational agent within 30 days prior to being registered for initial therapy.
- No prior therapy with a Ras pathway inhibitor or anti-angiogenic agent.
- No other active cancers.
- Females must not be breastfeeding.
- No active clinically serious infections as judged by the treating investigator (> CTC v3, Grade 2) including known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- No major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration for initial therapy.
- No anticipation of need for major surgical procedure during the course of the study.
- No minor surgical procedures such as fine needle aspirations or cone biopsies within 7 days prior to registration for initial therapy.
- No history of allergic reactions to drugs utilizing the vehicle polysorbate 80 + polyethylene glycol (etoposide).
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to registration for initial therapy.
- No use inhibitors or inducers of the cytochrome p450 system CYP3A4 enzyme or other medications such as aprepitant, ketoconazole, itraconazole, quinidine, digoxin, cyclosporine, ritonavir, grapefruit products, St. John's Wort, rifampin (rifampicin), carbamazepine, phenytoin, dexamethasone, and phenobarbital.
- No evidence or history of bleeding diathesis or coagulopathy.
- No serious non-healing wound, ulcer, or bone fracture.
- No known or suspected allergy to sorafenib.
- No uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management.
- No thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within 6 months prior to registration for initial therapy.
- No pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks prior to registration for initial therapy.
- No hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to registration for initial therapy.
- No condition that impairs patient's ability to swallow whole pills or any malabsorption problem.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Investigational Treatment
Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
|
Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Time to Disease Progression (TTP)
Délai: 18 months
|
18 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
La survie globale
Délai: 18 mois
|
18 mois
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Nasser Hanna, M.D., Hoosier Oncology Group, LLC
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Tumeurs
- Maladies pulmonaires
- Tumeurs par site
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs pulmonaires
- Carcinome pulmonaire non à petites cellules
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Agents antinéoplasiques phytogéniques
- Inhibiteurs de la topoisomérase II
- Inhibiteurs de la topoisomérase
- Inhibiteurs de protéine kinase
- Étoposide
- Cisplatine
- Sorafénib
Autres numéros d'identification d'étude
- HOG LUN06-107
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .